Lunai Bioworks Inc. (LNAI)

NASDAQ: LNAI · USD

$0.23

-0.02 (-8.2%)· Recorded snapshot

Market cap	1.2M
Revenue (ttm)	52K
Net income (ttm)	-3.6M
EPS (ttm)	-$1.06
Shares out	5M
Volume	486,330
Beta	0.35

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 52K
Net income (ttm): -3.6M
EPS (ttm): -$1.06
Market cap: 1.2M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROEn/a

P25 -113.8P50 -46.5P75 -0.9

ROICn/a

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All LNAI indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001527728
Company name	Lunai Bioworks Inc.
Country	United States
Country code	US
CUSIP number	29350E302
Earnings date	2026-11-13
Earnings time	amc
Employees	12
Employees change	-17
Employees growth	-58.62%
Enterprise value	$943,219
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US29350E3027
Last earnings date	2026-10-13
Last refreshed	2026-10-28
Last stock split date	2026-05-22
Last stock split type	Reverse
Market cap	$1.2M
Market cap category	Nano-Cap
Next earnings date	2026-11-13
Options	Yes
Price	$0.23
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	LNAI
U.S. state	California
Website	https://www.lunaibioworks.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-457.48%
EV/Sales	18.64x
FCF / EV yield	-545.93%
FCF yield	-443.69%
P/S ratio	22.93x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-15,129.29%
Pretax margin	-6,851.98%
Profit per employee	$-296,873
Revenue per employee	$4,333
ROA	-54.11%
ROA (5Y)	-22.13%
ROCE	87.71%
SBC / revenue	1,729.24%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	1
Net income growth quarters	1
Net income growth years	1
Revenue growth (QoQ)	48.27%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1,238
Depreciation and amortization	$58,418
EBIT	$-7.9M
EBITDA	$-7.8M
EPS	$-1.06
FCF per share	$-1.05
Financing cash flow	$6.4M
Free cash flow	$-5.3M
Free cash flow minus SBC	$-6.2M
Gross profit	$51,992
Investing cash flow	$543,462
Net borrowing	$593,629
Net cash flow	$1.6M
Net income	$-3.6M
Operating cash flow minus SBC	$-6.2M
Operating income	$-7.9M
Revenue	$51,992
Stock-based compensation	$899,068

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-76.19
Book value per share	$-1.96
Goodwill	$6M
Interest coverage	-33.46
Long-term assets	$7.9M
Long-term liabilities	$56,248
Net cash (debt)	$223,264
Net cash / market cap	18.73%
Piotroski F-Score	1
Property, plant and equipment	$12,015
Shareholders' equity	$-9M
Tangible book value	$-16.9M
Tangible book value per share	$-3.67
Total assets	$9.9M
Total cash	$1.7M
Total debt	$1.5M
Total liabilities	$19M
WACC	9.67%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.01
Current assets	$2M
Current liabilities	$18.9M
Current ratio	0.11
Net working capital	$-17.2M
Quick ratio	0.09
Working capital	$-16.9M
Working capital turnover	-0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-62.89%
Dividend yield	0%
Shareholder yield	-62.89%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.36
1D price change	-8.24%
1M price change	-88.03%
1M total return	-88.03%
1W price change	-55.15%
1W total return	-55.15%
1Y price change	-97.25%
1Y return CAGR	-97.26%
1Y total return	-97.25%
20-day SMA	$0.80
200-day SMA	$2.95
3M price change	-89.64%
3M total return	-89.64%
3Y price change	-99.89%
3Y return CAGR	-89.78%
3Y total return	-99.89%
50-day SMA	$1.65
50-day SMA vs 200-day SMA	50under200
52-week high	$13.28
52-week high date	2025-11-20
52-week low	$0.20
52-week low date	2026-10-28
5Y price change	-99.97%
5Y return CAGR	-79.81%
5Y total return	-99.97%
6M price change	-90.64%
6M total return	-90.64%
All-time high	$1,102.39
All-time high date	2021-12-01
All-time low	$0.20
All-time low date	2026-10-28
Average true range (ATR)	$0.17
Average volume	667.8K
Beta (1Y)	0.62
Beta (2Y)	1.76
Beta (5Y)	0.35
Change from 52-week high	-98.26%
Change from 52-week low	14.53%
Change from all-time high	-99.98%
Change from all-time low	14.19%
Change from open	0.74%
Day's gap	-8.91%
Dollar volume	$112,683
High price	$0.24
Low price	$0.20
Monthly RSI	37.32
Open price	$0.23
Position in 52-week range	74.06%
Premarket change	-3.37%
Premarket close	$0.25
Premarket price	$0.24
Premarket volume	27.8K
Previous close	$0.25
Price vs 150-day SMA	-90.19%
Price vs 20-day SMA	-71.05%
Price vs 200-day SMA	-92.16%
Price vs 50-day SMA	-85.97%
Relative volume	0.73
RSI	14.24
Sharpe ratio	-0.72
Sharpe ratio (3Y)	-0.6
Sharpe ratio (5Y)	-0.35
Sortino ratio	-1.44
Sortino ratio (3Y)	-1.01
Sortino ratio (5Y)	-0.55
Volume	486.3K
Weekly RSI	26.57
YTD price change	-96.73%
YTD total return	-96.73%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	4.2M
Float percentage	83.99%
Shares change (QoQ)	45.32%
Shares change (YoY)	62.89%
Shares held by insiders	15.81%
Shares held by institutions	3.9%
Shares outstanding	5M
Short % of float	3.5%
Short % of shares	2.94%
Short ratio	3.3 days

Deeper analysis on LNAI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LNAI report

Is a complete LNAI research report available?

No complete published report is available for Lunai Bioworks Inc. (LNAI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Lunai Bioworks Inc. (LNAI)

Price

Financial snapshot

Fair-value bridge

Latest news · LNAI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All LNAI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LNAI

Frequently asked questions